Personality in Adults Who Were Born Very Preterm

por Hertz, Christin L., Mathiasen, René, Hansen, Bo M., Mortensen, Erik L., Greisen, Gorm
Publicado 2013

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

por Overgaard, Rune V., Hertz, Christin L., Ingwersen, Steen H., Navarria, Andrea, Drucker, Daniel J.
Publicado 2021

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial

por Prakash, Prashanth S, Rosenstock, Julio, Cariou, Bertrand, Christiansen, Erik, Hertz, Christin l, Montanya, Eduard, Nielsen, Morten Abildlund, Knop, Filip K
Publicado 2022

Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospecti...

por Khunti, Kamlesh, Hertz, Christin L., Husemoen, Lise Lotte N., Mocevic, Emina, Nordsborg, Rikke B., Piltoft, Johanne S., Bain, Stephen C.
Publicado 2021

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

por Pratley, Richard E., Crowley, Matthew J., Gislum, Mette, Hertz, Christin L., Jensen, Thomas B., Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B.
Publicado 2021

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-lab...

por Buse, John B, Bode, Bruce W, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Nielsen, Morten A, Pieber, Thomas R
Publicado 2020

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program

por Kumar, K B Sharan, Dungan, Kathleen M, Hertz, Christin L, Mellibin, Linda, Nielsen, Morten Abildlund, Sorrig, Rasmus, Woo, Vincent C, Vilsboll, Tina
Publicado 2022